Adweek is pleased to announce the winners of its annual Brand Genius Awards. Now in their 27th year, the awards recognize the talented men and women behind the most inventive, […]
In 2015, GlaxoSmithKlein and Novartis completed a deal worth more than $20 billion that combined the two companies' assets. In November of that year, various sources reported that the newly created company planned to launch a review of its agency partners to effectively reset its global relationships.
GlaxoSmithKline is conducting a global review of media planning and buying for its consumer healthcare brands, and it comes as no surprise, given the company's recent asset swap with Norvartis.